NCT01371786View on ClinicalTrials.gov

A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Allergic Rhinitis (AR)
Interventions
DRUG

ciclesonide nasal aerosol

A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister

DRUG

mometasone Aqueous (AQ) nasal spray

A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle

Trial Locations (1)

NG11 6JS

Quotient Clinical, Ruddington Fields

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT01371786 - A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler | Biotech Hunter | Biotech Hunter